ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.650,20
2,81%
S&P 500
5.949,91
1,83%
US Dollar vs BRL
6,0218
0,13%
Bitcoin
99.180,18
-1,33%
Brent Oil
81,075
-0,74%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) Notícias

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNDX
DataHoraFonteTítuloCódigoCompanhia
15/01/202519:34PR Newswire (US)Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesNASDAQ:SNDXSyndax Pharmaceuticals Inc
13/01/202509:00PR Newswire (US)Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/01/202523:20PR Newswire (US)Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/01/202509:00PR Newswire (US)Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/01/202518:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
20/12/202419:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/12/202409:30PR Newswire (US)Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/12/202420:15PR Newswire (US)Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/12/202418:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
27/11/202409:00PR Newswire (US)Syndax Announces Participation at the Citi 2024 Global Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/11/202419:29PR Newswire (US)Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/11/202409:00PR Newswire (US)Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202418:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202418:01PR Newswire (US)Syndax Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202411:01PR Newswire (US)Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202411:00PR Newswire (US)Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202411:00PR Newswire (US)Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
04/11/202418:01PR Newswire (US)Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/11/202408:00PR Newswire (US)Syndax Announces Participation in November Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
29/10/202408:00PR Newswire (US)Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
18/09/202418:15PR Newswire (US)Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseaseNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/08/202417:15Business WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
15/08/202407:26Business WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/08/202418:34Business WireIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
12/08/202408:00PR Newswire (US)Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/08/202417:05PR Newswire (US)Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
29/07/202408:01PR Newswire (US)Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
25/07/202408:00PR Newswire (US)Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
17/06/202410:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
14/06/202408:00PR Newswire (US)Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 CongressNASDAQ:SNDXSyndax Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNDX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
GOLL4
GOL PN
BOV
BOBR4
BOMBRIL PN
BOV
AZEV4
AZEVEDO PN
BOV
IRBR3
IRB BRASIL ON
BOV
BRKM5
BRASKEM PNA
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados